HIV - Benchmarking Rapid Antiretroviral Uptake

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-02-02

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Historically, HIV antiretrovirals have differed markedly in their speed of market uptake. Now, to win market share in an already mature market, newly launched products need not only a superior profile but also a first-class pre-launch program. Datamonitor analysis has dissected four interdependent pre-launch activities known to influence uptake and compliment company operational sales strategies.


Scope

  • Review of expanded access programs, including numbers, location, length of time and range of participants
  • Detailed examination of late-phase trials, including an assessment of comparators and comments from opinion leaders on trial design
  • Insight into Company strategies for pre-launch dissemination of data, including conference attendance, journal articles and physician interaction
  • Analysis of post-launch product positioning and marketing strategies, using case studies, and their applicability for the future


    • Report Highlights
    As the HIV market moves towards maturity, promotion and marketing efforts are becoming increasingly important in ensuring rapid market penetration. An analysis of recent product launches provides case-studies for companies looking to launch new antiretrovirals and highlights the need for coherent product development and launch strategies.

    Within HIV clinical practice, it is becoming recognized that EAPs are considered the 'true launch' of a new product, and successful programs are thought to have contributed greatly to the success of Kaletra, Reyataz and Viread. The larger EAPs, run for longer periods of time, have raised 'real-life experience'.

    Datamonitor's opinion leader research placed most emphasis on the late stage clinical trial design. Those Phase III clinical trials which used up-to-date comparator drugs, were sufficiently powered and did not contain any inherent protocol biases in terms of administration and patient eligibility, were the most favored by the expert community.


    Reasons to Purchase

  • Understand patient segmentation relevant to pipeline products and validate internal forecasts/market potential for these products
  • Analyze the competitive environment at the time of product launch to ensure maximum rapid uptake of new antiretrovirals
  • Devise a coherent and comprehensive drug development and launch program to ensure lasting product commerical success

    • Table of Contents

    Other users found this report page using the following search terms: hiv ccr5 integrase haart hiv market antiretroviral share kaletra launch reyataz antiretrovirals gsk value

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.